Sunday, September 7, 2025

Medipharm Labs Receives Australian Drug Import License

Medipharm Labs (TSX: LABS) announced this morning that the firm has received an importation license from the Australian Department of Health, Drug Control Section, enabling the firm to import Schedule 4 drugs into the country. The step is a critical one, in that it gets Medipharm closer to executing upon its international strategy.

Now that the Medipharm Labs has acquired the key importation license, the firm will be able to submit for import permits for the importation of cannabis, cannabinoids, and cannabis resin. Once imported, the product will be finalized by Medipharm Labs Australia Pty into tinctures and other product forms.

The final step for the execution of Medipharm Labs’ Australian strategy will involve receiving GMP certification from the Therapeutic Goods Association. The certification will enable the firm to ship GMP-certified cannabis products to the European Union, including Germany, as a result of a Mutual Recognition Agreement between Australia and the EU.

No timeline was provided for the receipt of GMP Certification at the firms Australian facility, however Medipharm identified that receiving such certification is critical to its global supply chain strategy.

The news this morning could not come at a better time for Medipharm, whom yesterday scrambled to instill investor confidence following the filing of a statement of claim in Ontario related to unpaid debts owed by Hexo Corp.

Medipharm Labs last traded at $2.98 on the TSX.

Information for this briefing was found via Sedar and Medipharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Orla Mining Q2 Earnings: Musselwhite Changes Everything

Endeavour Silver Q2 Earnings: Growth Isn’t Always Pretty

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Recommended

ESGold Outlines $24.3 Million NPV For Tailings Reprocessing Project

First Majestic Encounters 711 g/t Silver Equivalent Over 8.0 Metres In Ongoing Exploration At Los Gatos

Related News

Medipharm Secures $37.8 Million In Convertible Notes

Medipharm Labs (TSX: LABS) this morning announced that it has secured aggregate gross proceeds of...

Monday, June 8, 2020, 08:55:34 AM

Medipharm Labs: Canaccord Drops Target To Just $0.10

On May 16, Medipharm Labs (TSX: LABS) reported its first quarter financial results. The company...

Tuesday, May 24, 2022, 11:37:00 AM

Medipharm Labs Sees Revenues Crater 65.8% Quarter Over Quarter

Medipharm Labs (TSX: LABS) has seen its revenues absolutely implode in a single quarter. The...

Thursday, June 18, 2020, 08:35:37 AM

MediPharm Labs: Canaccord Slashes Price Target Following Q4 Results

Earlier this week, Medipharm Labs (TSX: LABS) reported their fourth quarter and 2020 year-end financial...

Friday, April 2, 2021, 09:00:00 AM

Medipharm Labs Reports Q4 Revenues Of $6.1 Million, Net Loss Of $30.9 Million

Medipharm Labs (TSX: LABS) this morning reported its fourth quarter financial results for 2020. Revenues...

Wednesday, March 31, 2021, 07:47:27 AM